Pessary Treatment Successful for Symptomatic Pelvic Organ Prolapse

WEDNESDAY, Feb. 24, 2021 -- About three-quarters of patients with symptomatic pelvic organ prolapse (POP) report successful pessary treatment at five-year follow-up, according to a study published online Feb. 24 in Menopause.

Congcong Ma, Ph.D., from the Peking Union Medical College Hospital in Beijing, and colleagues conducted a prospective observational study involving 312 women with symptomatic POP who received pessary treatment between November 2013 and July 2015. Patients were initially fitted with a ring pessary with support, and those who failed were fitted with a Gellhorn pessary. For five years, 265 patients with successful pessary fitting were followed.

The researchers found that 180 of 239 patients continued pessary use after five years (75.3 percent continuation rate) and 26 were lost to follow-up. Over time, there was a decrease in discontinuation rates, from 8.7 to 2.7 percent at one and five years, respectively. Potential discontinuation risk factors included total vaginal length <7.5 cm, improvement in Urinary Impact Questionnaire-7 scores <50 percent at three months, and incapability of self-care (odds ratios, 2.7, 2.1, and 2.6, respectively).

"The vaginal pessary is an effective treatment in patients with symptomatic POP, with a high continuation rate and minor complications," the authors write.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Read this next

Repeat Postvasectomy Semen Analyses Down Under New Guidelines

FRIDAY, Jan. 15, 2021 -- After publication of the 2012 guidelines defining vasectomy success as either azoospermia or rare nonmotile sperm, men undergoing vasectomy had a lower...

Prostate Cancer Pathology Not Worse With Delayed Surgery

FRIDAY, Dec. 11, 2020 -- Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.